AVEO Pharmaceuticals, Inc. Announces Timing for First Quarter 2010 Financial Results, Webcast and Conference Call
CAMBRIDGE, Mass., Apr 22, 2010 (BUSINESS WIRE) --AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company's first quarter ended March 31, 2010 will be released before the market opens on Thursday, April 29, 2010. The management team of AVEO will also host a conference call and live webcast to discuss the company's financial results, recent developments and guidance for 2010 at 9:00 a.m. (EDT) on Thursday, April 29, 2010. The call can be accessed by dialing 1-866-783-2140 (domestic) or 1-857-350-1599 (international), five minutes prior to the start of the call and providing the passcode 18748077. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 64121444. The replay will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the AVEO website at investor.aveopharma.com. A replay of the webcast will be archived on the company's website for two weeks following the call.
AVEO Pharmaceuticals (NASDAQ: AVEO) blends a proprietary cancer biology platform with drug development and commercial expertise to discover and develop targeted cancer therapeutics. The company's lead product, tivozanib, is an oral, triple VEGF receptor inhibitor with potential for a best-in-class profile. Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types. AVEO's proprietary, integrated cancer biology platform offers the company a unique advantage in oncology drug development that both increases the probability of clinical success and provides a discovery engine for high-value targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.
SOURCE: AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
David Johnston,Chief Financial Officer, 617-299-5810
Caton Lovett, 910-232-7166